Premium
Cytotoxicity and efficacy evaluation of polymeric nanoparticles containing resveratrol and quercetin for use on drug eluting stents
Author(s) -
Kleinedler Jim,
Foley John,
Dugas Tammy
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.640.2
Subject(s) - restenosis , resveratrol , vascular smooth muscle , biocompatibility , cytotoxicity , platelet , platelet activation , pharmacology , angioplasty , thrombosis , quercetin , medicine , viability assay , chemistry , stent , biomedical engineering , cell , smooth muscle , surgery , in vitro , immunology , biochemistry , organic chemistry , antioxidant
Current generation coronary drug‐eluting stents (DES) used to treat restenosis are associated with unintended complications including potentially fatal late‐term thrombosis and hypersensitivity reactions. This provides a platform for novel engineered device therapies that exhibit increased biocompatibility and promote vascular healing after angioplasty. Resveratrol and quercetin have antimitogenic actions on vascular smooth muscle cells (VSMC) and inhibit both platelet and inflammatory cell activation. Our aim was to develop a stent coating that releases these drugs within a therapeutic range and provides an extended release profile to inhibit cascades responsible for restenosis and thrombosis. Stainless steel flats were coated with arborescent polyisobutylene‐polystyrene polymer (arbIBS) applied using the novel NanoElectrospray(TM) process. To determine DES‐mediated effects, assays were conducted on flats incubated in transwells in the presence of vascular cells. These included measures of cell viability, platelet activation, and cell proliferation. Results from this study indicate that arbIBS exhibits no cytotoxicity, and that the nanoparticles release resveratrol and quercetin at the therapeutic level, reducing platelet activation and VSMC proliferation. Ongoing experiments are aimed at introducing these DES into an animal model of angioplasty for further evaluation. Grant Funding Source R01‐ HL082472